/
AVIR
$4.61+$0.12 (+2.67%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$359.3M
80M shares
52-week range
$2.78 – $6.45
50% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-16.87
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $48.6M | $351.4M | $0 | $0 | $0 | $0 |
| Cost of revenue | $17.0K | $17.0K | $38.0M | $167.2M | $62.4M | $70.1M | $83.4M | $0 |
| Gross profit | −$17.0K | −$17.0K | $10.6M | $184.2M | −$62.4M | −$70.1M | −$83.4M | $0 |
| Gross margin | — | — | 21.8% | 52.4% | — | — | — | — |
| R&D | $6.7M | $10.2M | $38.0M | $167.2M | $88.8M | $132.8M | $145.4M | $148.0M |
| Operating income | −$9.5M | −$14.6M | −$11.0M | $138.4M | −$130.7M | −$164.2M | −$192.9M | −$180.9M |
| EBITDA | −$9.5M | −$14.6M | −$11.0M | $138.6M | −$110.8M | −$119.6M | −$131.8M | −$164.1M |
| Net income | −$9.1M | −$13.5M | −$10.9M | $121.2M | −$115.9M | −$136.0M | −$168.4M | −$158.3M |
| Net margin | — | — | -22.5% | 34.5% | — | — | — | — |
| EPS (diluted) | -0.90 | -0.16 | -0.13 | 1.37 | -1.39 | -1.63 | -2.00 | -1.94 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-1.93 | $-2.19–$-1.65 | 1 |
| 2027 | $30M | $-1.39 | $-1.64–$-1.12 | 1 |
| 2028 | $71M | $-0.95 | $-0.95–$-0.95 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.01
Price
$4.61
Implied downside
-78%
Peer comparison
Atea Pharmaceuticals, Inc. Common Stock
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
www.ateapharma.com- Employees
- 55
- IPO / List date
- Oct 30, 2020
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds AVIR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,166,400 | $6.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2018-02-14 | 1-for-11reverse |
Recent trades on TradeandTell
No one on the platform has traded AVIR yet.
